Predicting Failure at Initiation of High-Flow Nasal Oxygen in Patients With COVID-19: Literature Review, Development and Internal Validation of a Prediction Model.
Daphne J T Sjauw, Matthijs L Janssen, Yasemin Türk, Carmen A T Reep, Leo Heunks, Sara J Baart, Evert-Jan Wils
{"title":"Predicting Failure at Initiation of High-Flow Nasal Oxygen in Patients With COVID-19: Literature Review, Development and Internal Validation of a Prediction Model.","authors":"Daphne J T Sjauw, Matthijs L Janssen, Yasemin Türk, Carmen A T Reep, Leo Heunks, Sara J Baart, Evert-Jan Wils","doi":"10.1002/resp.70254","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>High-Flow Nasal Oxygen (HFNO) can reduce the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF) from viral pneumonias, like COVID-19. Early prediction of HFNO failure is useful for timely decision-making at HFNO initiation. This study aimed to develop a prediction model for HFNO failure using predictors available just prior to HFNO initiation in patients with COVID-19 AHRF and compare its performance to existing models.</p><p><strong>Methods: </strong>This multicenter, prospective observational cohort study included hospitalized patients from 10 centers in the Netherlands between December 2020 and July 2021. Adults who tested positive for SARS-CoV-2, had no treatment limitations, and initiated HFNO for hypoxemia were included. The primary outcome was HFNO failure, defined as the event of endotracheal intubation. Pre-defined candidate predictors were selected by multivariable logistic regression for prediction model development. Internal validation was conducted using bootstrapping.</p><p><strong>Results: </strong>Out of 608 patients, 277 (46%) experienced HFNO failure. Independent predictors of HFNO failure included (odds ratio [95% CI]): age (1.02 [1.00-1.03]), urea (1.04 [1.00-1.08]), platelet count (0.94 [0.92-0.97]), respiratory rate (1.05 [1.02-1.08]), oxygen saturation (0.89 [0.84-0.94]), and FiO<sub>2</sub> (conventional oxygen 10-15 L/min vs. < 10 L/min: 3.00 [1.71-5.29], 15 L/min vs. < 10 L/min: 4.95 [3.19-7.70]) prior to HFNO initiation. The model C-statistic was 0.767; 95% CI [0.727-0.803], with excellent calibration (intercept: -0.005, slope: 1.001), and stable performance after internal validation.</p><p><strong>Conclusions: </strong>This newly developed model, using variables available at HFNO initiation, effectively predicted HFNO failure in hospitalized hypoxemic patients due to COVID-19 pneumonia with good performance.</p><p><strong>Registration number clinical trial: </strong>Dutch Trial Registry: DTR, NL9067.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"798-807"},"PeriodicalIF":7.2000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432548/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/resp.70254","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: High-Flow Nasal Oxygen (HFNO) can reduce the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF) from viral pneumonias, like COVID-19. Early prediction of HFNO failure is useful for timely decision-making at HFNO initiation. This study aimed to develop a prediction model for HFNO failure using predictors available just prior to HFNO initiation in patients with COVID-19 AHRF and compare its performance to existing models.
Methods: This multicenter, prospective observational cohort study included hospitalized patients from 10 centers in the Netherlands between December 2020 and July 2021. Adults who tested positive for SARS-CoV-2, had no treatment limitations, and initiated HFNO for hypoxemia were included. The primary outcome was HFNO failure, defined as the event of endotracheal intubation. Pre-defined candidate predictors were selected by multivariable logistic regression for prediction model development. Internal validation was conducted using bootstrapping.
Results: Out of 608 patients, 277 (46%) experienced HFNO failure. Independent predictors of HFNO failure included (odds ratio [95% CI]): age (1.02 [1.00-1.03]), urea (1.04 [1.00-1.08]), platelet count (0.94 [0.92-0.97]), respiratory rate (1.05 [1.02-1.08]), oxygen saturation (0.89 [0.84-0.94]), and FiO2 (conventional oxygen 10-15 L/min vs. < 10 L/min: 3.00 [1.71-5.29], 15 L/min vs. < 10 L/min: 4.95 [3.19-7.70]) prior to HFNO initiation. The model C-statistic was 0.767; 95% CI [0.727-0.803], with excellent calibration (intercept: -0.005, slope: 1.001), and stable performance after internal validation.
Conclusions: This newly developed model, using variables available at HFNO initiation, effectively predicted HFNO failure in hospitalized hypoxemic patients due to COVID-19 pneumonia with good performance.
Registration number clinical trial: Dutch Trial Registry: DTR, NL9067.
期刊介绍：
Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery.
The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences.
Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
